AstraZeneca and CSPC Forge AI-Driven Drug Discovery Partnership

The latest announcement is out from AstraZeneca ( (AZN) ).

On June 13, 2025, AstraZeneca announced a strategic research collaboration with CSPC Pharmaceuticals to advance AI-enabled drug discovery. This partnership aims to develop novel oral candidates for treating various chronic diseases, leveraging CSPC’s AI-driven drug discovery platform. The collaboration enhances AstraZeneca’s presence in China and follows a significant investment in Beijing earlier this year, potentially impacting the company’s operations and market positioning. CSPC will receive an upfront payment and is eligible for further milestone payments, while AstraZeneca gains rights to commercialize successful candidates globally.

The most recent analyst rating on (AZN) stock is a Hold with a $74.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the AZN Stock Forecast page.

Spark’s Take on AZN Stock

According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.

AstraZeneca’s overall stock score is driven by strong financial performance and positive earnings call outcomes, highlighting robust growth and strategic pipeline advancements. While technical indicators suggest neutrality, the valuation appears high, indicating limited upside potential given current prices.

To see Spark’s full report on AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, focusing on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are available in over 125 countries and are used by millions of patients worldwide.

Average Trading Volume: 5,411,408

Technical Sentiment Signal: Strong Buy

Current Market Cap: $229.4B

See more insights into AZN stock on TipRanks’ Stock Analysis page.